![](https://www.pymnts.com/wp-content/uploads/2023/05/shutterstock_670842601-2-e1580391152470.jpg)
The company established by Martin Shkreli, also known as the “Pharma Bro” for increasing the cost of an old drug by 4,000%, has submitted a petition for Chapter 11 bankruptcy in Delaware.
Vyera Pharmaceuticals, formerly known as Shkreli’s Turing Pharmaceuticals, along with its parent company Phoenixus AG and four other companies, have filed for Chapter 11 protection as per documents from the US Bankruptcy Court for the District of Delaware. The case filing for Vyera mentions plans for a sale or liquidation of the “liquidating debtors” with the aim of preserving Phoenixus.
Rea more: Pharma Bro’s Former Drug Company To Settle Antitrust Class Action
According to court papers filed on Wednesday, Vyera stated that Shkreli instructed the company to carry out anticompetitive actions even while he was serving a prison sentence for securities fraud charges.
Vyera, formerly known as Turing Pharmaceuticals, has between $10 million and $50 million in assets and between $1 million and $10 million in liabilities, according to a Chapter 11 petition filed in Delaware bankruptcy court.
Vyera filed a Chapter 11 plan in court on Wednesday, laying out it its intent to repay creditors through asset sales.
Featured News
FTC and State Attorneys General Sue John Deere Over Repair Restrictions in Antitrust Case
Jan 15, 2025 by
CPI
Enbridge Wins Legal Battle Against Ducere’s Antitrust Allegations
Jan 15, 2025 by
CPI
GOP Pushes for Antitrust Authority Consolidation Under DOJ in New Legislation
Jan 15, 2025 by
CPI
Canadian Government Approves Bunge-Viterra Merger with Conditions
Jan 15, 2025 by
CPI
SEC Sues Elon Musk Over Delayed Disclosure of Twitter Stock Ownership
Jan 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 19, 2024 by
CPI
Effective Interoperability in Mobile Ecosystems: EU Competition Law Versus Regulation
Dec 19, 2024 by
Giuseppe Colangelo
The Use of Empirical Evidence in Antitrust: Trends, Challenges, and a Path Forward
Dec 19, 2024 by
Eliana Garces
Some Empirical Evidence on the Role of Presumptions and Evidentiary Standards on Antitrust (Under)Enforcement: Is the EC’s New Communication on Art.102 in the Right Direction?
Dec 19, 2024 by
Yannis Katsoulacos
The EC’s Draft Guidelines on the Application of Article 102 TFEU: An Economic Perspective
Dec 19, 2024 by
Benoit Durand